Dr. Matthieu CHAREYRE France

Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.

Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.

Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.

Company Size (Fulltime employees)
Year of foundation
2013
Please specify your partnering goal
Fundraising
Headquartner in China
Biotech/Pharma Category
Assets Information 1
CN109862905A published 2019-06-07 | Methods for treating osteoarthritis by administering linked variants of growth hormone and somatostatin | The present invention relates to the treatment of osteoarthritis. In particular, the present invention relates to peptides for use in the treatment of osteoarthritis
Biotech/Pharma Asset Stage
Medtech Information 1
Diagnostic companion kit OsteoArthritis
Medtech Development Stage
Slides Deck
(png, 430.99KB)
Dr. Matthieu CHAREYRE
Regulaxis
LinkedIn logo Chief Business Development Officer - Global Pharmaceutical Operations 
Functionality

Cheng Charles United States

Knightway Capital is a global investment firm focusing on med-tech, fin-tech, and legal-tech investments. We commit people, knowledge, and capital to empower revolutionary ideas and help exceptional entrepreneurs build enterprises contributing to the common good and long-term prosperity of society.

We are founded by a team of experienced professionals and executives with extensive industry expertise and backed by the most connected and influential investors and partners in the business ecosystem.
Partnering Objectives
Headquartner in China
Knightway Capital
Partner 

Mr Murthy Chavali India

Satya is an early-stage Oncology biotech focused on discovering small molecule NCEs, with novel targets against well-established Oncogenes, Tumor suppressors and Synthetic Lethal targets. Satya's team has over 50 years' combined discovery expertise, having worked on over 75 targets and delivered 15 clinical candidates
Website:
www.satyarx.com
Company Size (Fulltime employees)
Year of foundation
2019
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Satyarx Pharma Innovations Private Limited
LinkedIn logo CEO 
Functionality

Nick Cheh China

FEBICO (Far East Bio-Tec. Co., Ltd.) was established in 1976. We have three main business segments: New Drug Development, Diagnostic Reagents, and Dietary Supplement .
We develop an anti-virus platform, FEM, to develop potential drug candidates.
We focus on developments of botanical drugs and biologics to resolve the unmet medical needs such as inflammation diseases (lung injury, liver inflammation, liver fibrosis), hepatitis B, and herpes.
Website:
www.febico.com
Company Size (Fulltime employees)
Year of foundation
1990
Partnering Objectives
Headquartner in China
Biotech/Pharma Asset Stage
Far East Bio-Tec. Co., Ltd
Director of BD 
Functionality

ming chen China

haitong
Website:
www.haitong.com
Partnering Objectives
Headquartner in China
haitong security
analyst 

Dr. Donghai Chen United States

Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

To continue our development, part of our strategies requires us to constantly seeking high-quality novel drug research and development programs that are open to collaboration opportunities. Relying on strong industry resources and connections built up throughout the years, we welcome partnerships in the following structures: equity investment, intermediary service and project incubation.
Company Size (Fulltime employees)
Please specify your partnering goal
equity investment and program incubation
Headquartner in China
Protheragen Inc.
Business Development Director 

Denise Chen China

GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ¥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.

Website:
www.szgig.com
Company Size (Fulltime employees)
Please specify your partnering goal
potential investing targets and collaborations
Headquartner in China
Medtech Development Stage
GIG
Partner 
Functionality

Lisha Chen China

HEC Pharm is the pharmaceutical subsidiaries of HEC Group. There has been a public company listed in Hong Kong in HEC Pharm, and another company will be listed in Shanghai next year.

HEC Pharm focuses on the development and commercialization of pharmaceuticals for the therapeutics of anti-infectious diseases, metabolism disorders and oncology. We are hunting for the opportunities of co-development and in-license of the candidates with the potential therapeutics in previous fields.
Website:
www.hec.cn
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
out-license, in-license and co-development opportunities hunting
Headquartner in China
HEC Pharm
Senior Business Development Manager 
Functionality

Anita Chen

L.E.K. Consulting is a global strategy consulting firm that specializes in corporate strategy, transaction services, and performance improvement. Founded in 1983, we now have more than 1,500 professionals located across major economies worldwide. Clients include Fortune 500, FTSE 100, Eurotop 300, and many of the largest firms in Asia-Pacific.

 

With a reputation for solving the most complex issues, L.E.K. collaborates closely with business leaders and their teams to accelerate the pace and precision of strategic decision-making. L.E.K. works across numerous industry sectors including a strong focus on the healthcare sector.

 

As a leading strategic advisor to the life sciences industry, L.E.K.’s clients include the largest and most advanced pharmaceutical, biotech, medical devices, tools and diagnostics companies. L.E.K.’s global team of life sciences professionals has expertise across all major industry segments and therapeutic areas, and we provide support at each stage of the product life cycle, from drug discovery to commercial optimisation.

 

L.E.K. hosts the Asia Pacific Life Sciences Centre of Excellence in partnership with the Singapore Economic Development Board (“EDB”). This Centre of Excellence (“CoE”) drives thought leadership and innovation to elevate the life sciences ecosystem both in Singapore and across the region.

Website:
www.lek.com
L.E.K. Consulting